Nabumetone Tablets

This product is a non-acidic non-steroidal anti-inflammatory drug, which is rapidly metabolized to 6-methoxy-2-naphthylacetic acid (6-MNA) in the liver and has antipyretic, analgesic and anti-inflammatory effects. 1 The anti-inflammatory, analgesic and antipyretic effects are related to the fact that the active metabolites of cabutimetone inhibit the synthesis of prostaglandins in inflammatory tissues. 2 Little effect on gastric mucosa: This product is a non-acidic, non-ionic prodrug, which has no obvious local direct effect on the gastric mucosa during the absorption process; at the same time, this product has little inhibitory effect on the physiological cyclooxygenase of the gastric mucosa. Therefore, the incidence of gastrointestinal mucosal erosion and bleeding caused by this product is low. 3 No effect on bleeding and coagulation: This product has no effect on the platelet aggregation induced in vitro in blood samples of healthy volunteers. There were no significant changes in bleeding time and coagulation tests.

Nabumetone. Molecular formula: C15H16O2 Molecular weight: 228.29

This product is white tablets.

Rheumatoid arthritis, osteoarthritis.

1Usual dosage for adults is 1.0g (2 tablets) orally, once a day. The maximum daily dosage is 2g, divided into two doses. Adults weighing less than 50kg can start with 0.5g (1 tablet) daily. Gradually increase to the effective dose. 2The dosage for children has not yet been established.

1. Gastrointestinal tract: nausea, vomiting, indigestion, diarrhea, abdominal pain and constipation, about 1% to 3%. Upper gastrointestinal bleeding, about 0.7%. In the cases using this product, the incidence of ulcers was 0.1% in the short-term treatment group (6 weeks to 6 months) and 0.95% in the long-term treatment group (8 years). The incidence of diarrhea increased with daily oral administration of 2g of nabumetone. 2. Nervous system: manifestations include headache, dizziness, tinnitus, sweating, insomnia, drowsiness, tension and dreaminess, with an incidence of less than 1.5%. 3. Skin: rash and itching, about 2.1%, edema, about 1.1%. 4. Rare or occasional adverse reactions include jaundice, abnormal liver function, anxiety, depression, paresthesia, tremor, dizziness, bullous rash, urticaria, dyspnea, asthma, allergic pneumonia, proteinuria, hematuria and blood

It is contraindicated for patients with active peptic ulcer or bleeding, severe liver function abnormalities, and allergies to this product and other non-steroidal anti-inflammatory drugs.

Precautions for children: Forbidden. Precautions for pregnancy and lactation: Pregnant women are not recommended to use this product in the last 3 months of pregnancy and during lactation. Precautions for the elderly: The elderly should maintain the lowest effective dose when using this product.

1. The absorption rate of this product is not affected by the combined use of aluminum hydroxide gel, aspirin or acetaminophen. However, it is generally not recommended to use two or more non-steroidal anti-inflammatory drugs at the same time. 2. There is no interaction between this product and the anticoagulant warfarin in healthy volunteers. However, there is no data on the combined use of these two drugs in patients. 3. The dose should be appropriately reduced when this product is used in combination with acetyl anticonvulsants and sulfonylurea hypoglycemic drugs. Overdose: When symptoms of poisoning occur due to overdose, gastric lavage or vomiting should be performed in time, and more than 60g of activated carbon should be taken orally to absorb the residual drugs in the digestive tract, and appropriate symptomatic and supportive therapy should be given.

Keep away from light and store in a sealed container.

0.5g

24 months